

Intention-to-treat

Unique ID	Study ID	Experimental	Comparator	Outcome	Weight	D1	D2	D3	D4	D5	Overall
Afshari 2012 T1	1.1	topiramate 50 mg	valproate 400 md	MDR	1	+	+	-	+	!	+
Ailani 2021 ato	2.1	atogepant 10 mg, 30 mg ; placebo		MDR	1	+	+	+	+	+	+
Ashina 2022 M	4.1	eptinezumab 100, 300	placebo	MDR	1	+	+	+	+	+	+
Ashina 2020 M	5.1	eptinezumab 100, 300	placebo	MDR	1	+	+	+	+	+	+
Ashtari 2008 IV	Old 1	topiramate 50 mg	propranolol 80 mg	MDR	1	!	+	+	+	!	!
Bavrasad 2010	6.1	topiramate 50 mg-75 mg	valproate 400-600 mg	MDR	1	+	+	+	+	!	!
Afshari 2012 AI	1.3	Topiramate 50 mg	Valproate 400 mg	AE	1	+	+	-	+	+	+
Ailani 2021 ato	2.3	atogepant 10 mg, 30 mg ; placebo		AE	1	+	+	+	+	+	+
Ashina 2022 Af	3.3	eptinezumab 100, 300	placebo	AE	1	+	+	+	+	+	+
Ashina 2020 Af	4.3	eptinezumab 100, 300	placebo	AE	1	+	+	+	+	+	+
Afshari 2012 5f	1.2	topiramate 50 mg	valproate 400 mg	50% resp	1	+	+	+	+	+	+
Ailani 2021 5of	2.2	atogepant 10 mg, 30 mg ; placebo		50% resp	1	+	+	+	+	+	+
Ashina 2022 5c	3.2	eptinezumab 100, 300	placebo	50% resp	1	+	+	+	+	+	+
Ashina 2020 5c	4.2	eptinezumab 100, 300	placebo	50% resp	1	+	+	+	+	+	+
Bigal 2015 MDI	7.1	ajovy 225 mg	placebo	MDR	1	!	+	+	+	+	!
Bigal 2015 5OR	7.2	ajovy 225 mg	placebo	50% rest	1	!	+	+	+	+	!
Bigal 2015 AE	7.3	ajovy 225 mg	placebo	AE	1	!	+	+	+	+	!
Buettner 2015	8.1	Simvastatin 20 mg BID + placebo		MDR	1	+	+	+	+	+	+
Buettner 2015	8.2	Simvastatin 20 mg BID + placebo		50% resp	1	+	+	+	+	+	+
Buettner 2015	8.3	Simvastatin 20 mg BID + placebo		AE	1	+	+	+	+	+	+
Cao 2014 MDR	9.1	Zhengtian 6 g TID	placebo	MDR	1	+	+	+	+	+	!
Cao 2014 AE	9.2	Zhengtian 6 g TID	placebo	AE	1	+	+	+	-	+	+
Cao 2016 MDR	10.1	zhengtian capsule 0.9g TI flunarizine		MDR	1	+	+	+	+	!	!
Cao 2016 50%f	10.2	zhengtian capsule 0.9g TI flunarizine		50% resp	1	+	+	+	+	!	!
Cao 2016 AE	10.3	zhengtian capsule 0.9g TI flunarizine		AE	1	+	+	+	+	+	!
Chowdhury 20:	11.1	topiramate 100 mg	propranolol 160 mg	MDR	1	+	+	+	+	+	+
Chowdhury 20:	11.2	topiramate 100 mg	propranolol 160 mg	50% resp	1	+	+	+	+	+	+
Chowdhury 20:	11.3	topiramate 100 mg	propranolol 160 mg	AE	1	+	+	+	+	+	+
Chowdhury 20:	12.1	erenumab 70 mg and 14c placebo		MDR	1	+	+	+	+	+	+
Chowdhury 20:	12.2	erenumab 70 mg and 14c placebo		50% resp	1	+	+	+	+	+	+
Chowdhury 20:	12.3	erenumab 70 mg and 14c placebo		AE	1	+	+	+	+	+	+
Croop 2021 MI	13.1	rimagepant 75 mg every ; placebo		MDR	1	+	+	+	+	+	+
Croop 2021 5o'	13.2	rimagepant 75 mg every ; placebo		50% resp	1	+	+	+	+	+	+
Croop 2021 AE	13.3	rimagepant 75 mg every ; placebo		AE	1	+	+	+	+	+	+
Detke 2018 MC	14.1	galcanezumab 120 mg	placebo	MDR	1	+	+	+	+	+	+
Detke 2018 5o'	14.2	galcanezumab 120 mg	placebo	50% resp	1	+	+	+	+	+	+
Detke 2018 AE	14.3	galcanezumab 120 mg	placebo	AE	1	+	+	+	+	+	+
Dodick 2018 M	15.1	erenumab 70 mg	placebo	MDR	1	+	+	+	+	+	+
Dodick 2018 5f	15.2	erenumab 70 mg	placebo	50% resp	1	+	+	+	+	+	+
Dodick 2018 Af	15.3	erenumab 70 mg	placebo	AE	1	+	+	+	+	+	+
Dodick 2019 M	16.1	eptinezumab 100, 300	placebo	MDR	1	+	+	+	+	+	+
Dodick 2019 5f	16.2	eptinezumab 100, 300	placebo	50% resp	1	+	+	+	+	+	+
Dodick 2019 Af	16.3	eptinezumab 100, 300	placebo	AE	1	+	+	+	+	+	+
Dodick 2018_2	17.1	erenumab 70 mg	placebo	MDR	1	+	+	+	+	+	+
Dodick 2018_2	17.2	erenumab 70 mg	placebo	50% resp	1	+	+	+	+	+	+
Dodick 2018_2	17.3	erenumab 70 mg	placebo	AE	1	+	+	+	+	+	+
Dodick 2010 M	18.1	onabotulinum toxin 155	placebo	MDR	1	+	+	+	+	+	+
Dodick 2010 5f	18.2	onabotulinum toxin 155	placebo	50% resp	1	+	+	+	+	+	+
Dodick 2010 Af	18.3	onabotulinum toxin 155	placebo	AE	1	+	+	+	+	+	+
Ferrari 2019 M	20.1	fremanezumab mo (675g placebo		MDR	1	+	+	+	+	+	+
Ferrari 2019 5c	20.2	fremanezumab mo (675g placebo		50% resp	1	+	+	+	+	+	+
Ferrari 2019 AE	20.3	fremanezumab mo (675g placebo		AE	1	+	+	+	+	+	+
Ganji 2021 MD	21.1	atorvastatin + valproate	valproate	MDR	1	+	+	+	+	+	+
Ganji 2021 AE	21.2	atorvastatin + valproate	valproate	AE	1	+	+	+	+	+	+
Goadsby 2020	22.1	atogepant 10 mg, 30 mg ; placebo		MDR	1	+	+	+	+	+	+
Goadsby 2020	22.2	atogepant 10 mg, 30 mg ; placebo		50% resp	1	+	+	+	+	+	+
Goadsby 2020	22.3	atogepant 10 mg, 30 mg ; placebo		AE	1	+	+	+	+	+	+
Goasby 2017 IV	23.1	erenumab 70 and 140 mg placebo		MDR	1	+	+	+	+	+	+
Goasby 2017 5f	23.2	erenumab 70 and 140 mg placebo		50% resp	1	+	+	+	+	+	+
Goasby 2017 A	23.3	erenumab 70 and 140 mg placebo		AE	1	+	+	+	+	+	+
Goncalves 201i	24.1	melatonin 3 mg	placebo and amitriptyline	MDR	1	+	+	-	+	+	+
Goncalves 201i	24.2	melatonin 3 mg	placebo and amitriptyline	50% resp	1	+	+	-	+	+	+
Goncalves 201i	24.3	melatonin 3 mg	placebo and amitriptyline	AE	1	+	+	-	+	+	+
Hedayat 2022 I	25.1	amitriptyline 25 mg	venlafaxine 37.5 mg	MDR	1	+	!	-	+	+	+
Hedayat 2022 I	25.2	amitriptyline 25 mg	venlafaxine 37.5 mg	AE	1	+	!	-	+	+	+

Low risk

Some concerns

High risk

D1 Randomisation process

D2 Deviations from the intended interventions

D3 Missing outcome data

D4 Measurement of the outcome

D5 Selection of the reported result

Hu 2022 MDR 27.1	galcanezumab 120 mg	placebo	MDR	1	+	+	+	+	+	+
Hu 2022 50% R 27.2	galcanezumab 120 mg	placebo	50% resp	1	+	+	+	+	+	+
Hu 2022 AE 27.3	galcanezumab 120 mg	placebo	AE	1	+	+	+	+	+	+
Lipton 2020 MI 32.1	eptinezumab 100, 300	placebo	MDR	1	+	+	+	+	+	+
Lipton 2020 50 32.2	eptinezumab 100, 300	placebo	50% resp	1	+	+	+	+	+	+
Lipton 2020 AE 32.3	eptinezumab 100, 300	placebo	AE	1	+	+	+	+	+	+
Mzadeh 2020 † 34.1	rosuvastatin 10 mg +propr propranolol 10 mg BID		MDR	1	+	+	+	+	+	+
Mzadeh 2020 † 34.2	rosuvastatin 10 mg +propr propranolol 10 mg BID		AE	1	+	+	+	+	+	+
Mullens 2020 † 35.1	galcanezumab 120 mg	placebo	MDR	1	+	+	+	+	+	+
Mullens 2020 † 35.2	galcanezumab 120 mg	placebo	50% resp	1	+	+	+	+	+	+
Mullens 2020 † 35.3	galcanezumab 120 mg	placebo	AE	1	+	+	+	+	+	+
Noruzzadeh 20 36.1	memantine 10 mg	placebo	MDR	1	+	+	+	+	+	+
Noruzzadeh 20 36.2	memantine 10 mg	placebo	AE	1	+	+	+	+	+	+
Reuter 2022 M 37.1	erenumab + plac	topiramate + plac	MDR	1	+	+	+	+	+	+
Reuter 2022 5C 37.2	erenumab + plac	topiramate + plac	50% resp	1	+	+	+	+	+	+
Reuter 2022 AI 37.3	erenumab + plac	topiramate + plac	AE	1	+	+	+	+	+	+
Reuter 2018 M 38.1	erenumab 140 mg	placebo	MDR	1	+	+	+	+	+	+
Reuter 2018 5C 38.2	erenumab 140 mg	placebo	50% resp	1	+	+	+	+	+	+
Reuter 2018 AI 38.3	erenumab 140 mg	placebo	AE	1	+	+	+	+	+	+
Rodriguez-Ley, 39.1	topiramate 50 mg	amitriptyline 50 mg	MDR	1	+	+	-	-	!	-
Rodriguez-Ley, 39.2	topiramate 50 mg	amitriptyline 50 mg	AE	NA	+	+	+	-	!	+
Sakai 2020 MD 40.1	galcanezumab 120 mg	placebo	MDR	1	+	+	+	+	+	+
Sakai 2020 50% 40.2	galcanezumab 120 mg	placebo	50% resp	1	+	+	+	+	+	+
Sakai 2020 AE 40.3	galcanezumab 120 mg	placebo	AE	1	+	+	+	+	+	+
Sakai 2021 MD 41.1	fremanezumab 675g quai	placebo	MDR	1	+	+	+	+	+	+
Sakai 2021 50% 41.2	fremanezumab 675g quai	placebo	50% resp	1	+	+	+	+	+	+
Sakai 2021 AE 41.3	fremanezumab 675g quai	placebo	AE	1	+	+	+	+	+	+
Sakai 2021_2 N 42.1	fremanezumab 225 mo a	placebo	MDR	1	+	+	+	+	+	+
Sakai 2021_2 5 42.2	fremanezumab 225 mo a	placebo	50% resp	1	+	+	+	+	+	+
Sakai 2021_2 A 42.3	fremanezumab 225 mo a	placebo	AE	1	+	+	+	+	+	+
Sakai 2019 MD 43.1	erenumab 28, 70, 140 mg	placebo	MDR	1	+	+	+	+	+	+
Sakai 2019 50% 43.2	erenumab 28, 70, 140 mg	placebo	50% resp	1	+	+	+	+	+	+
Sakai 2019 AE 43.3	erenumab 28, 70, 140 mg	placebo	AE	1	+	+	+	+	+	+
Silberstein 201 44.1	fremanezumab 675g quai	placebo	MDR	1	+	+	+	+	+	+
Silberstein 201 44.2	fremanezumab 675g quai	placebo	50% resp	1	+	+	+	+	+	+
Silberstein 201 44.3	fremanezumab 675g quai	placebo	AE	1	+	+	+	+	+	+
Silberstein 202 45.1	eptinezumab 100, 300	placebo	MDR	1	+	+	+	+	+	+
Silberstein 202 45.2	eptinezumab 100, 300	placebo	50% resp	1	+	+	+	+	+	+
Silberstein 202 45.3	eptinezumab 100, 300	placebo	AE	1	+	+	+	+	+	+
Silberstein 200 46.1	topiramate 100 mg	placebo	MDR	NA	+	+	-	+	+	-
Silberstein 200 46.2	topiramate 100 mg	placebo	AE	NA	+	+	-	+	+	-
Silberstein 200 47.1	topiramate 100 mg	placebo	50% resp	NA	+	+	-	+	+	-
Silberstein 201 48.1	gabapentin 1800 and 240	placebo	MDR	NA	+	+	+	+	+	+
Silberstein 201 48.2	gabapentin 1800 and 240	placebo	50% resp	NA	+	+	+	+	+	+
Silberstein 201 48.3	gabapentin 1800 and 240	placebo	AE	NA	+	+	+	+	+	+
Skjarevski 201: 49.1	galcanezumab 120 mg an	placebo	MDR	1	+	+	+	+	+	+
Skjarevski 201: 49.2	galcanezumab 120 mg an	placebo	50% resp	1	+	+	+	+	+	+
Skjarevski 201: 49.3	galcanezumab 120 mg an	placebo	AE	1	+	+	+	+	+	+
Skjarevski 201: 50.1	galcanezumab 120 mg an	placebo	MDR	1	+	+	+	+	+	+
Skjarevski 201: 50.2	galcanezumab 120 mg an	placebo	AE	1	+	+	+	+	+	+
Smith 2020 MC 51.1	eptinezumab 100, 300	placebo	MDR	1	+	+	-	+	+	-
Smith 2020 50: 51.2	eptinezumab 100, 300	placebo	50% resp	1	+	+	-	+	+	-
Smith 2020 AE 51.3	eptinezumab 100, 300	placebo	AE	1	+	+	-	+	+	-
Sonbolestan 2C 52.1	enalapril 5 mg BID	placebo	MDR	NA	!	+	+	+	+	!
Sonbolestan 2C 52.2	enalapril 5 mg BID	placebo	50% resp	NA	!	+	+	+	+	!
Stauffer 2018 † 53.1	galcanezumab 120 mg an	placebo	MDR	1	+	+	+	+	+	+
Stauffer 2018 † 53.2	galcanezumab 120 mg an	placebo	50% resp	1	+	+	+	+	+	+
Stauffer 2018 † 53.3	galcanezumab 120 mg an	placebo	AE	1	+	+	+	+	+	+
Sun 2016 MDR 55.1	erenumab 70 mg	placebo	MDR	1	+	+	+	+	+	+
Sun 2016 50%: 55.2	erenumab 70 mg	placebo	50% resp	1	+	+	+	+	+	+
Sun 2016 AE 55.3	erenumab 70 mg	placebo	AE	1	+	+	+	+	+	+
Takeshima 202 56.1	erenumab 70 mg	placebo	MDR	1	+	+	+	+	+	+
Takeshima 202 56.2	erenumab 70 mg	placebo	50% resp	1	+	+	+	+	+	+
Takeshima 202 56.3	erenumab 70 mg	placebo	AE	1	+	+	+	+	+	+
Tepper 2017 M 57.1	erenumab 70 mg and 140	placebo	MDR	1	+	+	+	+	+	+
Tepper 2017 5: 57.2	erenumab 70 mg	placebo	50% resp	1	+	+	+	+	+	+
Tepper 2017 AI 57.3	erenumab 70 mg	placebo	AE	1	+	+	+	+	+	+

Wang 2021 MC 59.1	erenumab 70 and 140 mg placebo	MDR	1	+	+	+	+	+	+
Wang 2021 50: 59.2	erenumab 70 and 140 mg placebo	50% resp	1	+	+	+	+	+	+
Wang 2021 AE 59.3	erenumab 70 and 140 mg placebo	AE	1	+	+	+	+	+	+
Yu 2022 MDR 60.1	erenumab 70 mg placebo	MDR	1	+	+	+	+	+	+
Yu 2022 50%RF 60.2	erenumab 70 mg placebo	50% resp	1	+	+	+	+	+	+
Yu 2022 AE 60.3	erenumab 70 mg placebo	AE	1	+	+	+	+	+	+
Diener 2007 M 61.1	topiramate 100 mg placebo	MDR	1	+	+	-	+	+	-
Diener 2007 5C 61.2	topiramate 100 mg placebo	50% resp	1	+	+	-	+	+	-
Diener 2007 A1 61.3	topiramate 100 mg placebo	AE	1	+	+	-	+	+	-